EGFR exon 21 L858R substitution mutation

EGFR exon 21 L858R substitution mutation is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 1 company, spanning 5 indications including First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations (in combination with lazertinib), Locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations that has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (in combination with carboplatin and pemetrexed), First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations (in combination with carboplatin and pemetrexed). Explore the targeted therapies, indications, testing methods, and companies developing EGFR exon 21 L858R substitution mutation drugs below.